- Home
- NLSP vs SOPH Comparison
NLSP vs SOPH Comparison
Compare NLSP & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- SOPH
- Stock Information
- Founded
- NLSP 2015
- SOPH 2011
- Country
- NLSP Switzerland
- SOPH Switzerland
- Employees
- NLSP N/A
- SOPH N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NLSP Health Care
- SOPH Health Care
- Exchange
- NLSP Nasdaq
- SOPH Nasdaq
- Market Cap
- NLSP 12.4M
- SOPH 231.8M
- IPO Year
- NLSP 2021
- SOPH 2021
- Fundamental
- Price
- NLSP $2.03
- SOPH $3.23
- Analyst Decision
- NLSP
- SOPH
- Analyst Count
- NLSP 0
- SOPH 0
- Target Price
- NLSP N/A
- SOPH N/A
- AVG Volume (30 Days)
- NLSP 193.3K
- SOPH 38.8K
- Earning Date
- NLSP 10-17-2025
- SOPH 11-04-2025
- Dividend Yield
- NLSP N/A
- SOPH N/A
- EPS Growth
- NLSP N/A
- SOPH N/A
- EPS
- NLSP N/A
- SOPH N/A
- Revenue
- NLSP N/A
- SOPH $69,688,000.00
- Revenue This Year
- NLSP N/A
- SOPH $16.60
- Revenue Next Year
- NLSP N/A
- SOPH $18.77
- P/E Ratio
- NLSP N/A
- SOPH N/A
- Revenue Growth
- NLSP N/A
- SOPH 7.32
- 52 Week Low
- NLSP $1.30
- SOPH $2.58
- 52 Week High
- NLSP $6.97
- SOPH $4.92
- Technical
- Relative Strength Index (RSI)
- NLSP 43.44
- SOPH 46.63
- Support Level
- NLSP $1.88
- SOPH $3.10
- Resistance Level
- NLSP $2.29
- SOPH $3.49
- Average True Range (ATR)
- NLSP 0.12
- SOPH 0.16
- MACD
- NLSP -0.01
- SOPH -0.02
- Stochastic Oscillator
- NLSP 36.59
- SOPH 31.71
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.